• Bright Future for LTO Tape Tech, QBAK a Sector Pioneer
• N2Power Upside Bullish Amid Burgeoning Gaming Market
• 12 Months of Positive Cash Flow, Solid Long-Term Fundamentals

Qualstar is one of the oldest names in data storage, with a track record stretching back to the company’s founding in 1984 as one of the first tape drive developers for PC and workstations. Having developed Linear Tape-Open (LTO) technology alongside industry giants HP (NYSE: HPQ) and IBM (NYSE: IBM) in 1998, QBAK is a storied outfit that famously helped offer a clear and viable choice in earlier days of the computing revolution when there was a great deal of confusion due to an increasingly complex tape storage market. And the company is now also known for their N2Power subsidiary’s superbly designed, highly efficient, power-dense, and ultra-small power supply units (PSUs), which are utilized in a wide variety of equipment across numerous industries.

LTO Tape, a Potential Answer to Tightening Cloud Storage Margins

Now, investors may not be aware of this, what with all the retail consumer-directed ballyhoo over the latest solid state drives, but seemingly ancient tape drive technology is actually pretty compelling. Particularly when it comes to handling archival data and backups, where the latest generation of LTO-7 drives have proven themselves in independent testing to be excellent solutions. SSG-NOW ran some tests in March on Ultrium cartridge (LTO tape specification optimized for capacity and performance) based LTO-7 tapes, finding them not only ready for use in a production environment, but easy to use thanks to the Linear Tape File System (LTFS) making them appear as just another mounted drive. Generation 8 of LTO Ultrium is slated to more than double storage space to 32 terabytes, with more than a 57 percent increase in speed, up to 1,180 megabytes per second.

Of the big three industrial-scale cloud storage players, Google (NASDAQ: GOOGL; GOOG) is the only one to really talk publicly about using tape in its storage architecture. Microsoft (NASDAQ: MSFT) often touts the tech, but is very hush-hush about its Azure platform build. And Amazon (NASDAQ: AMZN) is apparently still living in the 90’s, when tape first fell out of favor, largely due to the emergence of cheaper and bigger disk drives, as well as problems associated with the terrible backup software they had back then.

The truth is that LTO, especially given the future roadmap for the tech (size and speed nearly doubling each generation), represents an ideal solution when it comes to reliability and performance in archival, backup, and storage tasks. Especially amid the rise of big data. And LTO is a solution which is also low-cost, preserving and enhancing the margins of the cloud business model, as we leap into the abyss of requiring zettabytes (one sextillion bytes) of storage in order to handle all the data we are producing. The increasingly rapid emergence of a world of connected, intelligent devices (Internet of Things, or IoT), and the big data analytics necessarily associated therewith, will put increasing pressure on cloud vendors to migrate into high-performance, low-cost solutions like tape.

QBAK Superbly Positioned to Exploit Underlying Market Dynamics

Not only do the kinds of tape solutions which Qualstar is known for have the power to save the economics of the post-zettabyte cloud model, these tape-based storage solutions also happen to represent easy access to an ideal cloud seeding workaround. This allows companies to bypass slow, contemporary networks when it comes to getting their data to the cloud. Due to an increasingly prevalent method where data is mirrored onto physical media like a tape drive and then physically sent to the cloud storage company’s server farm, cloud seeding via couriers is quickly becoming standard operating procedure for many.

Notably, there are several other key factors that set tape storage technology out as clear winner moving forward. Native write speeds of 300 MBps or greater (SSG-NOW was clocking rates of 750 MBps on readily-compressible documents like Word files and PDFs) is one of the greatest reasons. The Linear Tape File System’s (LTFS) super easy backup and restore workflow is another key aspect, which is inherently similar to disk-to-disk mirroring, but without the need for special backup software.

Considering $203 billion plus estimates for the big data and analytics market by 2020 (a nearly 12 percent CAGR), Simi Valley-headquartered QBAK looks to be in an extremely favorable position. Qualstar’s Simply Reliable™ XLS architecture is one of the most attractive solutions on the market today for growing data centers, due to proven flexibility, modularity, and reliability. Using self-contained, standalone LRMs (library resource modules) as the core, this architecture is also easily expandable for big capacity via MEMs (memory expansion modules).

The strong data management and storage offerings from this company, like the XLS-89000 MEM unit, will no doubt see Qualstar slicing off an ever larger slice of a growing pie, as cloud vendors awaken to the performance, scalability and cost benefits of such LTO architectures. The XLS-89000 boasts an incredible 16.13 petabytes of storage at maximum compression using LTO-7 (6.45 PB native), can hold 1,075 tape cartridges, and can be easily “daisy chained” with either type of XLS enterprise library system (XLS‑832700 or XLS‑8161100). This allows for field expandability up to 7,500 cartridges.

It is important for investors to understand how this easy extensibility and scalability translates directly into ease of use for operators, making these well-thought-out designs as intuitive, as they are powerful. QBAK’s patented Compass Architecture carousel technology allows for ridiculously high-density storage of 758 terabytes (uncompressed) per square foot, while still enabling the robotic tape handler to function in a gentle-motion profile, leading to improved reliability from this vital system. Whether a company is just starting out and wants a single, automated, high-capacity rack mountable tape library like the RLS-8350 (expandable by up to 8x via RLS-85120 modules), or is ready to enter the big leagues with a fully-expanded XLS setup, Qualstar is a one-stop shop for robust storage.

N2Power a Potential Sleeper Hit

The increasing probability of data ending up on tape is an important trend for investors following the growth of the data market – and it holds true whether a company is doing backup and archival in-house, or handing off to a cloud service. This is very bullish for QBAK’s enterprise library system business, but the company’s N2Power subsidiary may hold even more promise. N2Power has developed a very healthy market for the company’s industry-spanning array of ultra-small, highly efficient power supplies, which feature some of the highest power densities on the market. The diminutive power supplies are green by design, with up to a 93 percent efficiency rating, a lower heat generation profile, and most units require little or no forced air cooling.

With a strong footing in various markets like gaming, IT (both PSUs and enclosures), medical, light industrial and high-power equipment, N2Power has accrued quite the reputation for its beefy little PSUs (power supply units). Leading to a strong foundational market position and deals like the recently announced (July 25) $0.6 million the company landed in multiple orders for PSUs set to ship over the next five months or so, from an existing, prestigious gaming industry customer. The global casino gaming market is set to expand at 10.16 percent through 2021 according to a recent report from Research and Markets. The US casino gaming market represents the lion’s share of the space and is set to hit $93 billion by 2020. And the broader global digital gaming market (minus mobile) is around $62.8 billion this year and is on-track to grow as a whole by around 6.2 percent CAGR through 2020, on the strength of continued user adoption rates, and factors such as eSports and VR.

This is a great cultural backdrop and market environment for QBAK’s N2Power, which has established itself as a favored provider of feature-rich gaming PSUs to a variety of customers, ranging from some of the top casino gaming and ATM machine developers, to LED/lighting, and other applications. The ultra-dense, efficient power supplies N2Power provides to OEM designers are much sought after, not only because they reduce thermal load and cooling requirements, which is cheaper on energy, but also because the greater density frees up crucial machine real estate to make more room for other components. N2Power makes some of the tiniest, most reliable 125W to 500W AC-DC PSUs in existence today.

Strong Bottom Line Makes a Nice End Cap

It’s little wonder then that QBAK’s Q2 results showed YoY net income up 116 percent, in part on strong sales growth, as well as product expansion in the N2Power unit. With a strong balance sheet and no debt, such data points as the 6.5 and 6.9 percent increases (respectively) in gross profit margins for the three- and six-month periods (compared to the same period in 2016) are something which should really stand out to investors as a sign of the company’s fitness. Even before taking note of a 22.8 percent reduction in operating expenses over the six month period.

Take a closer look, visit http://www.qualstar.com/index.php

• Strategic acquisitions driving company growth, offering unique opportunities for investment
• Company completed Cranbury International acquisition, expanding portfolio and international reach
• Product roster further expands with VR training materials and 3D animations

Innovative EdTech company ProBility Media Corp (OTCQB: PBYA) is solidifying its position on the e-learning and training market via a series of recent acquisitions and new service and product offerings. With a declared goal of building the first full-service career advancement and training brand for skilled trades, ProBility is offering a combination of training and educational materials with virtual reality-based products for modeling training and 3D animation to an expanding international market.

The Houston, Texas-based company has just completed the acquisition of Vermont-based provider of education and training materials Cranbury International, thus gaining access to a wide range of new products destined for government institutions and private sector markets in several countries, including Brazil, Colombia, Trinidad, Mexico and many others. Aside from increasing its international reach and customer base, the acquisition will allow ProBility to introduce several of its own e-learning and virtual reality programs to new markets, at the same quality standards Cranbury has been adhering to since its creation in 2010.

Virtual reality has been a major component of ProBility’s product roster for a while, being used successfully for crane operator training, and the technology’s role is set to increase further as a result of ProBility’s joint venture with Industrial3D Corp., a provider and developer of 3D modeling, 3D animation and interactive media. Under the name ProBility Immersive Technologies, the joint venture specializes in creating interactive media and virtual reality content for ProBility’s current educational offerings, as well as for any custom products designed for clients who want to conduct their training in-house.

The joint venture has enhanced ProBility’s portfolio with over 200 3D animations targeting the industries it already serves, such as energy, medical manufacturing, engineering, etc., and it also enables the company to significantly expand its comprehensive offering of career advancement, training and compliance materials for more than 60 skilled trades.

The move came shortly after ProBility took a larger share of the educational market for the electrical contractor industry, estimated at $130 billion, following the acquisition of W Marketing, Inc., a provider of National Electrical Codes to the construction and electrical industries with a vast library of educational courses and exam preparation materials. In addition to strengthening ProBility’s financial position, the acquisition will allow the company to become one of the largest wholesale providers of National Fire Protection Association electrical codes in the United States.

The company has also expanded into the field of safety and security with the launch of an online training place, the ProBility Safety Academy – the result of a joint venture with Range Guard and Investigations Vice President Jonah Nathan. The Texas-accredited academy offers training, exam materials and courses for various security and safety fields including police science, public safety, private security, private investigation and criminal justice.

ProBility’s strategic acquisitions policy is making the company an appealing opportunity for investors in the e-learning and training space who are looking for ways of tapping into a growing organization serving dozens of industries and helping bring skilled trades and businesses into the 21st century. With an impressive portfolio of training and education programs, both online and in print, the company aims to change the landscape for small and medium businesses by offering them access to quality training materials typically only available to enterprise firms. Through its ever-growing product offerings and its acquisition policy, ProBility is set to position itself as a market leader in the e-learning sector and a high-quality source of testing, education and career advancement services.

For more information, visit the company’s website at www.ProBilityMedia.com

• Current telemedicine model is fragmented with little to no up sell
• Millions of Americans live in areas with little to no comprehensive health care
• MIHI building nationwide telemedicine network, making MIHI sole practitioner to millions

An estimated 80 million Americans live in rural areas where access to medical services is extremely limited. Identified as Medically Underserved Areas by the government, these regions suffer from a chronic shortage of not only primary care physicians but, even more critically, specialty care physicians. Targeting these medically underserved areas, Medical Innovation Holdings, Inc. (OTC: MIHI) intends to deliver much needed medical care while simultaneously developing the foundation of its unique business model.

Utilizing telemedicine to connect specialty physicians to diverse rural areas, MIHI is committed to expanding and disrupting the traditional telemedicine business model, building a national network of physicians and patients, and vertically integrating multiple health care-related products and services across multiple platforms throughout its entire network. Because specialists are primarily based in urban areas, rural patients do not have direct access to these specialists and are forced to travel great distances, wasting time and money to get the care they need.

The company’s business model provides much needed specialty practice medical services to underserved rural patients in the setting of their primary practice provider. It also provides the rural physician with administrative support, additional income through more product and service offerings, and the ability for the rural practice to grow exponentially while providing access to specialist practitioners.

The company’s proprietary telemedicine platform brings together multiple modalities of telemedicine to create a virtual multi-specialty practice within a rural primary clinic practice. The business model is designed to greatly increase the access to specialty providers, including, neurology, dermatology, ear nose and throat, tele-stroke, management of high-risk pregnancy, psychiatry, dermatology, endocrinology, pediatrics, cardiology, nephrology, pulmonology, OBGYN, maternal and fetal, and others.

With the intent of driving shareholder and market value, MIHI is creating various subsidiaries that will become the foundation designed to both service and support its network of medically underserved markets. MIHI has already created both 3Point Care and BKare Diagnostics as distinct revenue drivers. 3Point Care is a management service organization (MSO) with an exclusive contract relationship with TeleLife MD to provide telehealth services to MIHI’s marketplace. BKare Diagnostics is a full scale provider of high quality laboratory and pharmaceutical services that supports the company’s entry into medical lab services, medical devices, and nutraceuticals.

With the ability to provide a vast array of health care-related services on its various technology platforms, the company intends to create a comprehensive health care-centric business ecosystem where multiple products and services can be offered. As the company expands its unique business model into a large national footprint, a nationwide network of underserved patients will receive much needed services and, in essence, make MIHI a sole practitioner and product provider to a large swath of the population.

To effectively service such a large and diverse population across such a vast geographical area, the company has identified multiple products and services such as nutraceutical supplements, CBD products, OTC homeopathic medicines, lab services and traditional pharmaceutical products to feed into the network and meet the demands of this new market. The scope of products and services is limited only by medical needs and opportunities with the company’s network.

Since any pretense of competition is primarily based on the current dysfunctional large hospital or holding company medical model, the company intends to expand unabated throughout the United States and transform the status quo or telemedicine.

For more information, visit the company’s website at www.MedicalInnovationHoldings.com

• Lexaria Bioscience Corp. featured in a Technical420 article praising the company’s recent developments
• Lexaria is improving and strengthening patent portfolio; 19 patent applications are pending in more than 40 countries
• Company executes partnership with NeutriSci International; joint venture allows LXRP to enter Asian market

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), an innovative company licensing proprietary technology for the delivery of bioactive compounds including cannabinoids, is a “plant-to-bloodstream” company expected to draw investors in the cannabis marketplace. Lexaria has patented and licenses a novel delivery system that infuses organically sourced hemp oil into the molecules of other substances.

Cannabidiol, noted for its anti-inflammatory, anxiolytic, antiemetic and antipsychotic effects, is just one of several compounds targeted by Lexaria for its unique oral ingestion technology, which allows more efficient delivery of bioactive substances via oral ingestion without the need for unhealthy inhalation or the addition of sweeteners commonly used to mask bitter tastes. Non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and vitamins are among the substances targeted by Lexaria’s new delivery method.

A recent article in Technical420 (http://dtn.fm/C5gjS), a provider of research and analysis of cannabis stocks, praised the company for several positive developments over the past few months.

Lexaria has 19 patent applications filed and pending in more than 40 countries worldwide. The company strengthened its intellectual property portfolio with its first U.S. patent, issued in October 2016. The patent protects Lexaria’s intellectual property for infusion of cannabinoid compounds in edible products. Lexaria’s unique process improves the taste and bioavailability of cannabinoid food ingredients.

Another strong development is Lexaria’s joint venture with NeutriSci International (TSX.V: NU), a Canadian public company, to produce and sell a line of healthy edible cannabinoid products. The two companies will produce a line of cannabinoid mouth-melt products using Lexaria’s technology and NeutriSci’s proprietary pterostilbene tablet. Pterostilbene is an antioxidant that’s chemically similar to Resveratrol – a natural compound found primarily in blueberries and Pterocarpus marsupium heartwood, according to the U.S. National Library of Medicine (http://dtn.fm/5BkqA).

The joint venture will operate as Ambarii Trade Corporations, and initial operations will be funded equally by Lexaria and NeutriSci. AMbarii’s plans include securing licensees in Canada, California and Colorado to produce mouth-melt products containing THC.

Lexaria is also venturing into the Asian market, as noted by the Technical420 article. Ambarii has entered into an LOI with Naturally Splendid Enterprises Ltd. (TSX.V: NSP) for production and distribution of the company’s sublingual full spectrum cannabidiol tablets in Japan and South Korea. With a population of 127 million, Japan is one of the world’s largest markets, and hemp oil containing cannabidiol is already legal in Japan. South Korea, with a population of 50 million, is expected to open its markets to hemp oil-sourced cannabidiol soon.

Lexaria will begin in vitro absorption studies to quantify improvements in absorption in human intestinal tissue and will conduct animal studies on whole-body reactions to the rapid and efficient delivery of cannabinoids, vitamins, NSAIDs and nicotine. Edible nicotine products could allow a healthier alternative to smoking, patches and nicotine gum. The article points out that the company’s R&D budget is fully funded from existing capital.

Lexaria has an improved cash position and an attractive valuation, the Technical420 article states, due to improved balance sheets and a much smaller warrant overhang. The company raised more than $1.7 million in April, and, from November 2016 through May 2017, the company raised more than $4 million in equity. Technical420 is “favorable” on these developments and expects to see significant advancement by Lexaria Bioscience.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• Drug candidate for top cause of death in the United States
• Genetically-targeted therapy increases chances of recovery
• Interim efficacy analysis soon to be conducted by the Data Safety Monitoring Board

Atrial fibrillation affects up to six million people in the U.S. The condition, if untreated, can lead to blood clots, stroke, heart failure and other heart-related complications, but many medications currently in use to treat it come with worrying side effects, perhaps because of their one-size-fits-all approach. In an effort to mitigate the unwanted, unintended action of these agents, ARCA Biopharma, Inc. (NASDAQ: ABIO) is applying a precision medicine approach, developing genetically-targeted therapies for cardiovascular diseases, as it works to bring its lead candidate for atrial fibrillation, Gencaro™, to market. The company believes that by tailoring medical treatment to the individual genetic characteristics of patients, more effective therapies will be enabled, patient outcomes will be improved and health care costs will go down.

Atrial fibrillation (AFib) is the most common kind of heart arrhythmia, a condition where the heart beats too fast, too slow, or in an irregular fashion. In a heart suffering from AFib, the regular pumping action of its upper chambers, the atria, is impaired. As a result, blood flow to the lower chambers, the ventricles, is impeded. AFib increases a person’s risk for stroke by four to five times compared with people who do not have it, and strokes caused by complications from AFib tend to be more severe than strokes with other underlying causes. AFib causes 15%–20% of ischemic strokes, which occur when blood flow to the brain is blocked by a clot or by fatty deposits called plaque in the blood vessel lining.

According to the Centers for Disease Control and Prevention (http://dtn.fm/sCD06), “more than 750,000 hospitalizations occur each year because of AFib… (and) the condition contributes to an estimated 130,000 deaths each year. (In addition), the death rate from AFib as the primary or a contributing cause of death has been rising for more than two decades.” AFib costs the United States about $6 billion each year, and medical costs for people who have AFib are about $8,705 higher per year than for people who do not have AFib.

Current treatments for AFib include drugs for heart rate control, drugs for heart rhythm control, and blood thinners. These medication, however, give rise to a plethora of side effects, including breast enlargement, diarrhea, low blood pressure, and heart failure, as well as psychological problems. One class of drugs that controls heart rate is known as beta-blockers; drugs of this type work by reducing heart rate, an example of which is ARCA’s lead candidate, Gencaro.

Gencaro (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator, now under evaluation in a clinical trial for the treatment and prevention of recurrent AFib in heart failure patients with reduced left ventricular ejection fraction, or HFREF. The company believes that Gencaro’s mechanism of action (MOA) differs from other beta-blockers because of its sympatholytic (norepinephrine lowering) and inverse agonism (inactivation of constitutively active receptors) properties. Genetic variations in receptors in the cardiovascular system of the general population vary, and these variations are thought to be a factor in how well patients respond to treatment. With Gencaro, ARCA has developed a formulation which interacts positively with a genotype, beta-1 389 arginine homozygous, found in approximately 50 percent of the U.S. population. Consequently, a Gencaro regimen promises a reduced range of side effects for a larger population of patients.

In June 2017, ARCA announced database lock for the GENETIC-AF interim efficacy analysis to be conducted by the trial Data Safety Monitoring Board (DSMB). Locking or closing a database ensures that no unauthorized or unintentional changes are made after the final data entry, check-up, and analysis. GENETIC-AF is a phase 2B/3 double-blind, clinical superiority trial comparing the safety and efficacy of Gencaro to an approved drug, TOPROL-XL, for the treatment and prevention of recurrent AFib in heart failure patients with reduced left ventricular ejection fraction (HFrEF). The company expects to announce the DSMB’s recommendation based on this interim analysis in August 2017. The Gencaro development program was previously granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

For more information, please visit www.ARCABio.com

• Proxy to shareholders seeks a reduction in Net Element’s common shares from 400 million to 100 million
• NETE reaches 30-month term stock purchase agreement with Cobblestone Partners
• Sets August 10 meeting with NASDAQ to present plan for listing compliance

Net Element, Inc. (NASDAQ: NETE) has proposed to shareholders a reverse split of its common stock at a ratio of between 1-for-10 and 1-for-30 on the proxy at its annual meeting in 2017 (http://dtn.fm/mod3S). It also plans to put to a vote of shareholders a reduction in common stock from 400 million shares to 100 million shares in the hope that fewer shares will result in an increase in the market price of its common shares.

NETE is a cloud-based global financial company that accepts electronic payments in an omni-channel environment. It processes payments in what is becoming a cashless economy at point-of-sale and on mobile devices. It also offers clients management tools in its systems. A Zack’s Research Report (http://dtn.fm/1uNBd) projects that the company will generate revenues of $74.6 million by 2018.

In the SEC filing of the proxy (http://dtn.fm/lIbk9), NETE said that it will appeal the NASDAQ market’s deficiency letter in a meeting on August 10. NETE said the purpose of the reverse stock split amendment is to decrease the number of outstanding shares of common stock and potentially increase the market price of its common stock. A stay of the decision by NASDAQ is in effect pending an appeal by the company.

“The company is considering several paths to regain compliance with the minimum bid price requirement, including, among other things, a reverse stock split,” the company said in the filing.

The proxy also detailed its July 5, 2017, agreement with Cobblestone Partners, LLC, to purchase up to an aggregate of $10 million of NETE’s common stock over the 30-month term of the purchase agreement. Proceeds from the agreement will be used by the company for working capital and general corporate purposes. The proposal, approved by shareholders in the proxy, would permit Cobblestone Partners to buy in excess of 19.99% of NETE’s outstanding shares, as per NASDAQ rules.

In a letter to shareholders (http://dtn.fm/i2aLL), NETE management also said that it has a program of cost cuts that should be realized by the third quarter of 2017.

For more information, visit the company’s website at www.NetElement.com

• Fundamental value drivers of InMed Pharmaceuticals are its drug development pipeline and proprietary biosynthesis technology in cannabinoid manufacturing
• Biopharmaceutical company already has two drug candidates – INM-085 and INM-750 – in the multi-billion dollar ocular and dermatology markets
• INM-085 and INM-750 target markets valued in excess of $5 billion and $1 billion, respectively

InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) study, which generated an article published in the European Journal of Pain (http://dtn.fm/UMfe5), sets the stage for more research into how a topically-applied drug can provide relief of chronic or acute pain without central side effects, according to Dr. Sazzad Hossain, chief scientific officer of InMed. It may eventually lead to a product which encompasses cannabinoid compounds targeting pain-related receptors in the body.

InMed is a Vancouver-based preclinical stage biopharmaceutical company specializing in the development of cannabinoid-based therapies using novel drug therapies and delivery systems. Value drivers for the company are its proprietary process for cannabinoid manufacturing and its drug candidate pipeline. It already has two preclinical product candidates. INM-085 has been developed for the treatment of glaucoma, an eye disease that accounts for a greater than $5 billion global market. The other is INM-750 for the treatment of orphan disease epidermolysis bullosa (EB), which is characterized by fragile skin. There are no approved therapies for the disease in this $1 billion market.

The InMed Pharmaceuticals article in the Journal (http://dtn.fm/lxT2B) focuses on how THC impacts the peripheral cannabinoid (CB) receptors CB1 and CB2. The results are that THC activates the CB1 receptor to provide analgesic relief without side effects. The study results suggest that THC could provide a novel approach to offer that relief through the peripheral application of cannabinoids.

The article is titled, “Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation.” The study was co-funded by Canadian non-profit organization Mitacs and InMed Pharmaceuticals. In a news release, Hossain, co-author of the findings report, said, “This study sets the stage for advanced work in various pain models to explore the role of several cannabinoid compounds, applied as topical agents, to target the CB1 and other pain-related receptors.”

The result could be a valuable approach in the cannabinoid treatment of severe pain. The model used in this study mimics the muscle pain of temporomandibular joint disorders (TMD) that affect the jaw muscle. TMD is a chronic pain condition that’s difficult to treat.

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board

• New Chinese economy has produced new Chinese consumer
• Consumer has pent up demand
• Moxian provides platform to motivate and move consumers to retail outlets

There’s little doubt that economic forces have transformed the Chinese consumer markets. The meteoric rise of middle-class households, a new generation of tech savvy consumers and the powerful pull of e-commerce all promise immense new consumer opportunities in China. A long time in the making, China’s consumer class has arrived.

China’s state run economy has pushed and pulled the country from subsistence agrarians to leading edge high-tech manufacturing with workers and consumers evolving along the way. Over 40 years in the making and with huge pent up demand, the new Chinese consumer class is ready to fully engage the twenty-first century. Technologically astute, the new Chinese consumer is poised to dramatically impact the economy of not only China but also the world. Companies that operate in and cater to this new megalith of consumption stand to be handsomely rewarded.

Moxian, Inc. (NASDAQ: MOXC) caters to and focuses on the new Chinese consumer and, importantly, bridges e-commerce to brick-and-mortar retail. Moxian provides small- and medium-sized brick-and-mortar businesses with cutting-edge turnkey solutions to attract and maintain customers. Free to the consumer, Moxian’s creative and socially interactive online platforms and mobile applications are moving the burgeoning Chinese consumer from online views to retail purchases at Moxian’s brick-and-mortar retail client locations. Moxian’s seductive social network integrates social media and business into a single platform that offers products, features and services that appeal to consumers, keeps them engaged and encourages them to refer new customers.

The company’s ingenious online platforms and mobile applications, the Moxian+ User app and the Moxian+ Business app, allow businesses to interface with both new and existing customers. These online interactions provide each business the data to analyze consumer likes, dislikes and trends. Moxian’s platforms provide businesses the ability to create, manage and promote individualized customer loyalty programs, targeted advertising campaigns and special promotions. These interactions between users and Moxian’s merchant clients drive retail traffic into the brick and mortar locations and give merchant clients the ability to study consumer behavior and custom-tailor offerings to consumers.

Moxian continues to expand its web platform in an effort to entice and draw in consumers to its business clients. The company just announced another strategic partnership with a major high end retailer (http://dtn.fm/NI6qO) that should provide synergies, new products and technologies and open new distribution channels in high-growth markets. “China’s retail industry is going through a major transformation where mobile payments, marketing tools and customer data analytics converge into one single platform, and Shewn is a good example of a nationwide merchant capitalizing on the power of such platform to improve its marketing efficiency,” James Tan, chief executive officer of Moxian, stated in the news release. “With the extension of our powerful Moxian+ mobile App platform to Shewn and its distribution network, we look forward to a mutually beneficial relationship between the two parties in years to come.”

Moxian is taking the initiative to capitalize on what is a generational opportunity, and it appears that the company is positioned to be amply rewarded.

For more information, visit the company’s website at www.Moxian.com

• NASDAQ Biotechnology Index up and climbing
• Developing new treatment for acute myeloid leukemia (AML)
• Lead candidate, Annamycin, now at phase II

Since a rising sea lifts all boats, it’s decidedly good news for Moleculin Biotech, Inc. (NASDAQ: MBRX) that the NASDAQ Biotechnology Index (NBI) is enjoying a spring tide. The index has offered a year-to-date return of over 17 percent and seems set to keep climbing. This benign environment gives Moleculin an opportunity to advance work on its leading anti-cancer drug candidates. The company has begun to identify and prepare testing sites in Europe and has already appointed a Lead European Principal Investigator.

Moleculin was featured on Business Insider (http://dtn.fm/8LbO7), in a piece that attributed the rise in the NBI to ‘recent FDA decisions and clinical trial developments’. Moleculin, a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, announced on August 3 that it had selected Bioscience SA (Bioscience), a Polish contract research organization (CRO) to begin identifying and preparing clinical testing sites in Poland for Annamycin. Annamycin is the company’s drug candidate for the treatment of relapsed or refractory acute myeloid leukemia (AML).

AML is a type of blood cancer that usually develops in cells destined to become leukocytes or immune cells. It stunts their development and, consequently, results in a profusion of immature cells. As these immature cells, also known as blast cells, continue to build up, they may find their way into the lymph nodes, the liver, the spleen, the testicles or the brain, with highly deleterious effect.

In 2016, about 21,380 people of all ages (11,960 men and boys and 9,420 women and girls) were diagnosed with AML in the United States, according to Cancer Net (http://dtn.fm/0pGqR). The condition is the second most common type of leukemia diagnosed in adults and children. It is rare for AML to occur before age 45, and the average age at the time of diagnosis is 67 years. However, roughly three-quarters of those who develop it die within five years.

Moleculin’s lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory AML. So far, there are promising indications that Annamycin can circumvent some of the problems encountered in current treatment regimens, such as the risk of cardiotoxity, where treatment drugs damage the heart, and multi-drug resistance. Moleculin also has two active pre-clinical small molecule candidates in the pipeline. The first is directed at modulating hard-to-target cell signaling mechanisms and appears capable of stimulating a patient’s natural immune system while also attacking tumors directly. The second candidate targets the metabolism of tumors and exploits a unique approach for crossing the blood brain barrier for the treatment of glioblastoma and other central nervous system malignancies.

Some of Moleculin’s anti-cancer drug candidates are based on license agreements with The University of Texas System on behalf of the MD Anderson Center. MD Anderson is one of the original three comprehensive cancer centers in the U.S., and, in 2016, was ‘ranked #1 for cancer care in the “Best Hospitals” report published by the U.S. News & World Report.’

For more information, please visit www.Moleculin.com

• Millions of Americans live in areas with little or no comprehensive health care
• MIHI establishing nationwide telemedicine network to provide specialty care
• Serving the underserved makes MIHI sole practitioner to millions

There’s no doubt that the U.S. health care system is fractured. Our patchwork quilt of health care services leaves many citizens isolated and medically stranded. Far beyond the current contentious health care debate, millions of Americans live in areas that have chronically suffered with little or no health care services. For various reasons of geography, economics or social circumstance, certain populations in the country have far too few primary care providers. Defined by the government as Medically Underserved Areas, recruiting physicians to these communities is challenging not only because of the population’s complex human needs and limited health care resources, but also due to a lack of available social amenities.

Decades ago, country doctors were common, but they are now scarce in the 21st century, creating a critical need for primary care physicians in rural areas. Small towns around the country face the loss of basic medical services, because they have so few doctors to run their clinics. Many attribute the dearth of rural doctors to the increasingly complex and specialized nature of medical practices and the rapid pace of technological advancement.

Within this void, Medical Innovation Holdings Inc. (OTC: MIHI) uses technology to target and serve these underserved. MIHI is addressing this pressing need by establishing a nationwide, multi-disciplinary specialist provider network to serve rural patients via a seamless, comprehensive and sophisticated telemedicine program. The company’s platform is designed to bring much needed access to quality health care in real time while generating substantial efficiencies and cost savings.

The company’s telemedicine platform offers a range of modalities of telemedicine to create a virtual multi-specialty practice bringing modern medicine to underserved communities. The company’s subsidiary, 3Point Care, provides personalized pairing of its specialty doctors with traditional primary doctors, connecting patients with specialty health care professionals.

With the ability to provide a vast array of health care-related services on its various technology platforms, the company intends to create a comprehensive health care-centric business ecosystem where multiple products and services can be offered. As the company expands its unique business model into a large national footprint, a vast network of underserved patients will receive much needed services and, in essence, make MIHI a sole practitioner and product provider to a large swath of the population.

For more information, visit the company’s website at www.MedicalInnovationHoldings.com